Methods of administering anti-TNFα antibodies

CAFC
  • US 9,017,680 B2
  • Filed: 11/14/2014
  • Issued: 04/28/2015
  • Est. Priority Date: 06/08/2001
  • Status: Active Grant
First Claim
Patent Images

1. A method of reducing signs and symptoms in a patient with moderately to severely active rheumatoid arthritis, comprising:

  • administering to said patient, in combination with methotrexate, a human anti-TNFα

    antibody,wherein the human anti-TNFα

    antibody is administered subcutaneously in a total body dose of 40 mg once every 13-15 days, andwherein the anti-TNFα

    antibody comprises an IgG1 heavy chain constant region;

    a variable light (“

    VL

    ) chain region comprising a CDR1 having the amino acid sequence of SEQ ID NO;

    7, a CDR2 having the amino acid sequence of SEQ ID NO;

    5, and a CDR3 having the amino acid sequence of SEQ ID NO;

    3; and

    a variable heavy (“

    VH

    ) chain region comprising a CDR1 having the amino acid sequence of SEQ ID NO;

    8, a CDR2 having the amino acid sequence of SEQ ID NO;

    6 and a CDR3 having the amino acid sequence of SEQ ID NO;

    4.

View all claims
    ×
    ×

    Thank you for your feedback

    ×
    ×